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Abstract
Background: Osteogenesis Imperfecta (OI) (OMIM %259450) is a heterogeneous group of inherited disorders
characterized by increased bone fragility, with clinical severity ranging from mild to lethal. The majority of OI cases are
caused by mutations in COL1A1 or COL1A2. Bruck Syndrome (BS) is a further recessively-inherited OI-like phenotype in
which bone fragility is associated with the unusual finding of pterygia and contractures of the large joints. Notably, several
studies have failed to show any abnormalities in the biosynthesis of collagen 1 in BS patientes. Evidence was obtained for
a specific defect of the procollagen telopeptide lysine hydroxylation in BS, whereas mutations in the gene PLOD2 have
been identified. Recently, several studies described FKBP10 mutations in OI-like and BS patients, suggesting that FKBP10 is
a bonafide BS locus.
Methods: We analyzed the coding region and intron/exon boundaries of COL1A1, COL1A2, PLOD2 and FKBP10 genes
by sequence analysis using an ABI PRISM 3130 automated sequencer and Big Dye Terminator Sequencing protocol.
Mononuclear cells obtained from the bone marrow of BS, OI patients and healthy donors were cultured and
osteogenic differentiation was induced. The gene expression of osteoblast specific markers were also evaluated during
the osteoblastic differentiation of mesenchymal stem cell (MSC) by qRT-PCR using an ABI7500 Sequence Detection
System.
Results: No mutations in COL1A1, COL1A2 or PLOD2 were found in BS patient. We found a homozygous 1-base-pair
duplication (c.831dupC) that is predicted to produce a translational frameshift mutation and a premature protein
truncation 17 aminoacids downstream (p.Gly278ArgfsX95). The gene expression of osteoblast specific markers BGLAP,
COL1A1, MSX2, SPARC and VDR was evaluated by Real Time RT-PCR during differentiation into osteoblasts and results
showed similar patterns of osteoblast markers expression in BS and healthy controls. On the other hand, when compared
with OI patients, the expression pattern of these genes was found to be different.
Conclusions: Our work suggests that the gene expression profiles observed during mesenchymal stromal cell
differentiation into osteoblast are distinct in BS patients as compared to OI patients. The present study shows for the
first time that genes involved in osteogenesis are differentially expressed in BS and OI patients.
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Background
Bruck Syndrome (OMIM %259450) is a rare disorder in
which joint contractures are associated with bone fragility
and, because of this OI-like phenotype, the diagnosis of
Osteogenesis Imperfecta (OI) is subsequently considered.
Patients with BS usually exhibit multiple joint contractures
and pterygia, as observed in arthrogryposis multiplex con-
genita. In the subsequent weeks, multiple fractures of the
ribs and long bones are detected, as well as a diaphyseal
bending, kyphoscoliosis, and persistent wormian bone in
the calvarium; these features are strongly reminiscent of OI
[1, 2]. In contrast to OI, these patients do not have blue
sclera or hearing loss. Mental development is also normal
and reports suggest an autosomal recessive inheritance pat-
tern, but only approximately 27 cases have been reported in
the literature [3]. Notably, several studies have failed to
show any abnormalities in the biosynthesis of collagen 1
and 2 as it can be noted in OI individuals [4], but recent
reports have shown that mutations in other genes, like
PLOD2 and FKPB10, can result in both BS and Autosomal-
Recessive OI (AR-OI) phenotypes with variable degrees of
bone fragility and joint contractures [5], suggesting the
necessity for reassessing the current classification of OI.
A specific defect of procollagen telopeptide lysine hy-
droxylation in BS and mutations in the gene PLOD2 have
been identified (BS type 2); yet, the clinical and radio-
graphic features of PLOD2-associated BS have not been
described in detail, and only a large family study showed
evidence of linkage to chromosome 17 (designated BS
type 1) [6]. Hydroxylysine residues have some important
functions in collagens, such as the role in stabilization of
the intermolecular collagen cross-links, which pattern has
been found to differ from tissue to tissue [7]. It has been
shown that the amount of hydroxyallysine-derived cross-
links is related to the irreversible accumulation of collagen
in fibrotic tissues whereas the inhibition of these cross-
links results in the formation of a collagen that is easier to
degrade and can thereby prevent unwanted collagen accu-
mulation [8]. An important step in this process is the cis-
trans isomerization of peptide bonds. This process can be
catalyzed by peptidylprolyl cistrans-isomerases (cyclophi-
lins and FKBPs), like FKBP65 [9].
Novel mutations in FKBP10, which encodes FKBP65,
have been reported to cause a recessive OI-like phenotype.
In a study of a cohort of consanguineous Turkish families
with moderately severe inherited OI, Alanay et al. (2010)
found mutations in FKBP10 and determined that FKBP10
mutations affect type I procollagen secretion, identifying a
previously unrecognized mechanism in the pathogenesis
of OI [10]. Kelley et al. (2011) also described FKBP10
mutations in five families with OI-like bone fragility in
association with congenital contractures [11]. These stud-
ies, combined with other published works, confirm that
FKBP10 is a bonafide BS locus [3, 12, 13].
Despite this, more research into BS and OI phenotypic
heterogeneity are necessary and there is little information
about gene expression in undifferentiated and differentiated
bone marrow stromal cells (BMSCs) from these patients.
Uzawa et al. (1999) showed that normal undifferentiated
BMSCs have low PLOD2 expression levels, whereas fully
osteoblast differentiated BMSCs exhibited a significantly
elevated level of PLOD2 mRNA, suggesting an association
between PLOD2 expression and the tissue-specific collagen
cross-linking pattern, which is important in the onset of
matrix mineralization [14].
Despite this, there is no information concerning PLOD2
and other genes expressed in BMSCs from BS patients.
Our work provides information about the gene expression
of undifferentiated and osteoblast differentiated BMSCs
from a BS patient compared with OI and health controls.
We have monitored the surface marker profile and the
differentiation potential of these cells during their in vitro
expansion. Finally, we have analyzed osteoblast specific
markers gene expression levels during osteogenic differen-
tiation. BS cells were also screened for COL1A1, COL1A2,
PLOD2 and FKBP10 mutations. Results showed that,
when compared with OI patients, the expression pattern
of osteoblastic specific genes was found to be different.
Methods
Clinical report
The patient - a boy- was the first child of non-
consanguineous parents born at term by caesarian section
in 2005 after an uneventful pregnancy. The patient’s weight
was 2910 g (Z-score = −1.7 SD) and his height was 43 cm
(Z-score = −4.0 SD). Fractures of the left arm and left
clavicle were diagnosed immediately after birth. During the
first 4 months, the boy had additional fractures of the ribs,
lumbar spine (L1), and left and right legs. At the age of
6 months, his weight was 5985 g and he was admitted for
the first time at the Medical School of Ribeirão Preto
Hospital, University of São Paulo. The boy had blue-gray
sclera and pterygia were present on both elbows and knees,
which had severe limited extension. He also showed con-
tractures at the wrists, bowed legs and bilateral clubfeet.
Radiographic exams of the long bones and skull revealed
diffuse osteopenia. Serum levels of calcium, phosphate and
parathyroid hormone determined at the age of 7 months
were considered normal. Thus, after the parents signed an
informed consent, the patient received the first dose of dis-
odium pamidronate, which was maintained over a period
of 5 years. Cyclical intravenous disodium pamidronate was
given as previously suggested by Glorieux and his group
[15]. Up to the age of 2 years, pamidronate was adminis-
tered over a period of 1 h by intravenous (i.v.) infusion at
the dose of 0.5 mg/kg for 3 days every 2 months. Up to the
age of 3 years, the patient was treated with pamidronate
over a period of 1 h i.v. at the dose of 0.75 mg/kg, for 3 days,
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every 3 months. The pamidronate dosage was thereafter
adjusted to 1 mg/kg, for 3 days, every 4 months. Only two
new fractures occurred throughout this period and the
patient was then able to sit up independently. Pterygia
persisted at both elbows and knees. His mental develop-
ment was normal. The treatment was well tolerated and no
side-effects were observed, except fever after administration
of the first dose. The patient became more active and less
agitated. This study was carried out with the approval of
the Medical Ethics Committee of the HC-FMRP-USP (No.
10188/2007), and an informed consent was obtained from
all the participants.
In vitro expansion of human bone marrow-derived stromal
cells
Mononuclear cell fractions (MNC) were derived from bone
marrow of four OI patients (aged 15–39 years (25,75 ±
9,97)), two normal donors (23 and 24 years), and one BS
patient (6 year old), who gave consent after full information
and approval by the Medical Ethics Committee of the HC-
FMRP-USP. All MNC were isolated from bone marrow
aspirates at iliac crest. MNC were seeded at a density of 1 ×
105 per cm2 and were cultured for 24 h. After this period,
non-adherent cells were removed by medium exchange.
The adherent cells were cultured in an expansion medium
containing alpha-minimum essential medium (Gibco), 15 %
FBS (Gibco), 100U/mL penincillin, 100 μg/ML strepto-
mycin, and 2 mM L-glutamine under a humidified atmos-
phere of 5 % CO2 at 37 °C. The medium was replaced three
times a week. After reaching a confluence of 75–85 %, cells
were detached with 0.05 % trypsin and were replated at a
density of 5 × 105 cells. Cells were expanded until the end
of the third passage, when osteogenic differentiation was
induced with an expansion medium supplemented with
0.01 mM dexamethasone, 200 μM ascorbic-acid-2-phos-
phate and 10 mM β–glycerophosphate. RNA was harvested
at seven time points during the osteogenic differentiation
period (D0, D + 1, D + 2, D + 7, D + 12, D + 17 and D+ 21).
In vitro differentiation of human bone marrow-derived
MSC in osteoblasts and adipocytes
For the induction of osteogenesis, MSC were seeded at a
density of 104 cells/cm2 in an expansion medium. After
24 h, the differentiation was induced by medium exchange.
The osteogenic differentiation medium was based on the
expansion medium supplemented with 0.01 mM dexa-
methasone, 200 μM ascorbic-acid-2-phosphate and 10 mM
β–glycerophosphate. In addition to the expansion medium,
the adipogenic differentiation medium contained 0.1 μM
dexamethasone, 50 μM indomethacin, and 5 μg/mL insulin.
The media were changed three times a week for 21 days.
Osteogenic differentiation was detected by Von Kossa
staining of mineralized matrix on day 14, whereas
adipogenic differentiation was detected on day 10 by a
Sudan II assay that stains adipocyte-specific fat vacuoles.
The Von Kossa assay was performed with silver nitrate.
The medium was removed and the cultures were washed
with PBS, fixed with 4 % paraformaldehyde for 15 min,
washed again with distilled water, and incubated with 5 %
silver nitrate for 30 min. After incubation, the staining
solution was removed and the cultures were washed with
5 % sodium thiosulfate. Next, the cells were stained with
Harris hematoxylin for 5 min. Finally, cells were washed
with distilled water so as to remove excess color.
For Sudan II staining, a 2 % Sudan stock solution in
ethanol was prepared. The medium was removed; the cul-
tures were washed with PBS, fixed with 4 % paraformalde-
hyde for 15 min, washed again with distilled water, and
incubated with Scarlet Sudan for 5 min. After incubation,
the staining solution was removed and the cultures were
washed with 70 % ethanol. Then, the cells were stained
with Harris hematoxylin for 5 min. Finally, the cells were
washed with distilled water for removal of excess color.
Cells were analyzed with an Axioscope 2.0 Zeiss micro-
scope equipped with an AxioCam HR camera (Carl Zeiss,
Germany). The cells were harvested and analyzed at 14
and 21 days for osteogenic and adipogenic differentiation,
respectively.
Surface marker profiling by flow cytometry analysis
For flow cytometry analysis, the cells were detached with
0.05 % trypsin and were washed with PBS. A volume of 1
x 105 cells per tube were stained for 15 min and were
afterwards incubated in an ice bath in the dark with direct
PE or FITC conjugated mouse anti-human monoclonal
antibodies (Becton Dickinson) recognizing CD45, CD14,
CD29, CD105, CD90, CD34, CD31, and CD73. After anti-
body incubation, the cells were washed with PBS/sodium
azide and were resuspended in PBS in the volume re-
quired for analysis. Immunoglobulin isotype incubation
was carried out as a negative control. FACS (Fluorescence
Activated Cell Sorting) analysis was performed with FAC-
Sort™ (Becton Dickinson).
RNA and DNA purification
Total RNA was isolated with TRIzol reagent (Invitrogen)
and concentration and quality were assessed with Nano-
drop 2000 spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, USA). The High Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems) was used
to synthesize cDNA of 1 μg RNA, following manufac-
turer’s recommendations.
Genomic DNA was obtained from undifferentiated
BMSCs in the third passage, using the Wizard Genomic
DNA Purification Kit (Promega) according to the manu-
facturer’s instructions. DNA concentration was assessed
with Nanodrop 2000 spectrophotometer (Thermo Fisher
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Scientific, Waltham, MA, USA) and quality was analyzed
by electrophoresis on 2 % agarose gel. For PCR reac-
tions, DNA was diluted to 100 ηg/μL.
Mutation analysis
DNA sequencing of PCR-amplified COL1A1, COL1A2,
PLOD2 and FKBP10 gene fragments covering the entire
coding region and intron/exon boundaries was carried
out using an ABI PRISM 3130 automated sequencer
and Big Dye Terminator Sequencing protocol. All pri-
mer sequences and the respective annealing tempera-
tures used for PCR amplification of COL1A1, COL1A2,
PLOD2 and FKBP10 are available as an Additional file
1. PCR reactions were performed with a total volume of
25 uL ((NH4)2SO4 2 M, Tris–HCl 2 M, MgCl2 1 M and
1 % Tween 20 Buffer, 2.5 μM of each primer at 5 pmol/
uL, 1.5 mM dNTP, 1U Taq DNA Polymerase (Biotools)
and 4 uL of DNA at 5 ng/uL). The amplification
parameters were: 94 °C for 6 min, 35 cycles of 94 °C for
1 min, annealing temperature for 1 min and 72 °C for
1 min. The founded mutations were confirmed in a
second sample through another PCR reaction with the
use of Platinum® Taq DNA Polymerase High Fidelity
(Invitrogen, São Paulo, Brazil), followed by sequencing.
Expression analysis
RT-PCR assays were performed to detect the expression
levels of osteoblast specific marker genes BGLAP
(osteocalcin), COL1A1 (collagen 1A1), MSX2 (homeo-
box gene MSX2), SPARC (osteonectin), and VDR (vita-
min D receptor) to prove the osteoblast phenotype. All
primer sequences used for PCR amplification are avail-
able as an Additional file 1. qRT-PCR amplification
mixtures contained 20 ng template cDNA, 2X Power
SYBR Green Master mix buffer (10 μL) (Applied Bio-
systems) and 400 to 600 nM forward and reverse
primers in a final volume of 20 μL. All reactions were
duplicated using an ABI7500 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA),
under the following conditions: 95 °C, for 10 min,
followed by 40 cycles, at 95 °C, for 15 s, and 60 °C, for
1 min. Total RNA input was normalized based on the
Ct values obtained for the housekeeping gene GAPDH.
Experiments with coefficients of variation greater than
5 % were excluded. For all reactions, each run was
completed with a melting curve analysis to confirm the
specificity of amplification and lack of primer dimers.
Reactions were run in triplicates and a no-template
control (NTC) and no-reverse transcription controls
(No-RT) were also included. The relative quantification
of gene expression was carried out using the mathematical
model described in Pfaffl et al. (2001). Gene expression
was analyzed using 1-way analysis of variance, followed by
a Kruskal-Wallis test with Prism 3.0 (GraphPad Software,
San Diego, CA, USA). All differences were considered
significant at values of P < 0.05.
Results
BS bone marrow-derived stromal cells and normal cells have
similar surface marker profiles and in vitro differentiation
potential
In order to evaluate patients BMSCs population, we ver-
ify that MSCs derived from BS patient have similar levels
of CD45-, CD14-, CD34-, CD31-, CD29+, CD13+, CD90
+, CD73+, and CD105+ surface markers compared with
OI and healthy donors MSCs (Additional file 2). Results
show that BS, OI, and normal donor BMSCs depicted
homogenous cell population, demonstrating that MSC
did not alter their physical and morphological properties
in response to the syndrome. BS derived cells also
showed regular osteogenic and adipogenic differentiation
abilities (Fig. 1).
Mutation analysis
All OI patients showed the characterized mutations in
COL1A1 or COL1A2 genes previously described [16]. In
COL1A1: 1 missense mutation (p. Gly290Glu) have been
identified in patient MOOI3, 1 nonsense mutation
(Arg1026Ter) have been identified in patient MOOI1
and 1 out-of-frame insertion mutation (p. Leu69-
GlufsX74) have been identified in patient MOOI4. In
COL1A2: 1 missense mutation (p. Gly835Ser) have been
identified in patient MOOI2. Those mutations lead to
amino acid substitutions that are probably responsible
for the observed phenotype. We also found two COL1A1
and one COL1A2 variations in BS patient that were con-
sidered as non-pathogenic, as they do not alter amino
acids [16].
In BS patient, no mutations were found in PLOD2 gene.
All 10 coding exons in the FKBP10 gene were analyzed by
DNA sequencing. We found a homozygous 1-base-pair
duplication (c.831dupC) in BS patient, which is the same
as reported by Alanay et al. (2010), Kelley et al. (2011) and
Caparros-Martin et al. (2013) [10, 11, 17] (Fig. 2). This
mutation is predicted to produce a translational frameshift
mutation and a premature protein truncation 95 aminoa-
cids downstream (p.Gly278ArgfsX95). NM_021939.3 was
the reference sequence used for FKBP10 cDNA analysis
and the mutation was confirmed in the heterozygous state
in only one of the progenitors from whom DNA was
available.
Expression of osteoblast specific marker genes
Osteogenesis was monitored by microscopy during the
entire in vitro differentiation period. The first signs of
calcification appeared as black regions within the cell
monolayer in approximately ten days. The maximum
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extracellular matrix calcification was observed after
21 days of differentiation.
We also observed similar patterns of expression of
osteoblast markers: BGLAP (osteocalcin), COL1A1 (col-
lagen 1A1), MSX2 (homeobox gene MSX2), SPARC
(osteonectin), and VDR (vitamin D receptor) (Fig. 3)
between BS and healthy controls osteoblasts. On the
other hand, when compared with OI patients, the ex-
pression pattern of these genes showed significantly
higher expression levels than those observed in OI pa-
tients, for which only a slight increase could be detected
during in vitro differentiation (Fig. 3).
Fig. 2 Schematic view of FKBP10 coding region showing a homozygous C duplication at position 831
Fig. 1 Adipogenic and Osteogenic differentiation of mesenchymal stem cells (MSCs) after passage 3. a. BS patient; not induced MSC; undifferentiated,
magnitude order: 630X. b. BS cells differentiated into adipocyte after staining with Sudan II-Scarlat assay, magnitude order: 630X c. BS cells differentiated
in osteoblast after staining with Von Kossa assay; magnitude order: 10X. d normal donor; not induced MSC; magnitude order: 100X. e. Normal donor cells
differentiated into adipocyte, magnitude order: 630X. Sudan II staining showed MSC adipogenic differentiation after 10 days. f. normal donor
cells differentiated in osteoblast; magnitude order: 10X. g. OI patient, undifferentiated MSC; magnitude order: : 630X. h. OI patient cells
differentiated into adipocyte; magnitude order: 630X i. OI patients’ cells differentiated in osteoblast; magnitude order: 10X. Von Kossa staining
showed mineralization nodules (black) and MSCs morphology changed from spindle to cuboid shape after 14 days
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Discussion
Bruck syndrome manifests with combined features of
arthrogryposis and osteogenesis imperfecta. The main fea-
tures are osteoporosis, bowing of the long bones, scoliosis
due to vertebral deformities, and congenital joint contrac-
tures. The presence of arthrogryposis differentiates this
syndrome from “classical” Osteogenesis Imperfecta [18],
but recent reports have shown that some mutations can
result in both BS and Autosomal-Recessive OI (AR-OI)
phenotypes with variable degrees of bone fragility and
joint contractures [5], calling for the reclassification of OI.
BS patients do not exhibit blue sclera or hearing loss and
present normal mental development, although the ex-
tremely low number of cases ever reported in the litera-
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Fig. 3 Gene expression of osteoblast markers measured by Real Time RT-PCR at seven different points (MSC, D + 1, D + 2, D + 7, D + 12, D + 17 and D
+ 21). Legend: OI1-4: Osteogenesis Imperfecta patients; BS: Bruck Syndrome patient; NBM1-2: normal bone marrow donors. Each value represents the
mean of two independent experiments
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The surface marker profile was analyzed by flow cytome-
try and revealed that BS, OI, and normal donor BMSCs
depicted homogenous cell population, demonstrating that
MSC did not alter their physical and morphological proper-
ties in response to the syndrome; this supports our observa-
tion that MSC maintained their undifferentiated phenotype
and remained capable of differentiating during ex vivo
expansion.
Our study has also shown that BMSCs from BS patients
are capable of undergoing osteogenic and adipogenic dif-
ferentiation when cultivated under appropriate conditions,
in the same way as OI patients and healthy control cells.
The time necessary for complete differentiation was also
similar, suggesting that their capacity for mesenchymal
lineage differentiation was not compromised.
Several studies have failed to show any abnormalities in
the biosynthesis of COL1A1 and COL1A2 from patients
with BS, as observed in the majority of OI individuals. In
our study, two COL1A1 and one COL1A2 synonym muta-
tions were found in the BS patient, but they did not cor-
respond to modifications in the amino acid sequence,
suggesting that these mutations are not responsible for
the observed phenotype.
Although all three described PLOD2 mutations associ-
ated to BS are located in exon 17, the entire coding region
of this gene was directly sequenced and no mutations were
found. PLOD2 mutations are described as a cause for BS
type 2, whereas another type 1 - BS - is associated with a
linkage to chromosome 17, as described by Bank et al.
[1999], who mapped the BS locus of an 18-centimorgan
region on chromosome 17p12.
Analyzing FKBP10 by DNA sequencing, a homozygous
1-base-pair duplication (c.831dupC) was found. This muta-
tion is predicted to produce a translational frameshift muta-
tion and a premature protein truncation (p.Gly278Argfs
X95). This mutation, also described by Alanay et al. (2010),
Kelley et al. (2011) and Caparros-Martin et al. (2013),
results in a stop codon 17 aminoacids downstream in the
third PPIase (peptidylprolyl cis-trans Isomerase) domain of
the FKBP65 protein, which is a known chaperone for type I
procollagen [9, 19] and that have been implicated the fold-
ing of the proline-rich tropoelastin monomer. Alanay et al.
(2010) showed aggregated intracellular type I procollagen
in FKBP65 mutant cells, suggesting a functional defect in
the chaperone activity of the FKBP65 that is consistent
among BS patients.
Type-I collagen is a heterotrimeric molecule composed
of two α1 chains and one α2 chain that is the predominant
matrix molecule in bones. The biosynthesis of collagen
molecule is a long and complicated process involving a
number of post-translational modifications. The hydroxyl-
ation of specific peptidyl lysine (Lys) residues is critical for
the glycosylation and cross-linking of the collagen mol-
ecule and is performed by lysyl hydroxylases (LH) [14].
Lys hydroxylation in the nontryple helical domains of the
collagen molecule is particularly important in determining
the cross-link patterns that are known to differ from one
tissue to another. Furthermore, several studies have dem-
onstrated the occurrence of overhydroxylation of Lys resi-
dues in type-I collagen in bone diseases. It has been long
speculated that there is more than one type of LH; in turn,
the tissue-specific collagen cross-linking pattern is, at least
in part, presumably related to differential expression of
the genes encoding LHs in the respective tissues.
In addition, we analyzed the gene expression of osteo-
genesis markers, such as BGLAP (osteocalcin), COL1A1
(collagen 1A1), MSX2 (homeobox gene MSX2), SPARC
(osteonectin), and VDR (vitamin D receptor), by qRT-PCR.
BGLAP, previously described as a late marker of developing
osteoblasts, was observed significantly up-regulated in
samples from BS and in healthy controls on the second
day of differentiation. Mineralization could not be ob-
served, though. COL1A1 is known to be an early marker of
osteoprogenitor cells [20]. Nonetheless, its highest level of
expression was only reached on day 12. The homeobox
gene MSX2, which is implicated in the osteoprogenitor cell
function [21] and is an up-stream regulator of RUNX2,
was up-regulated during the final phase of differentiation
[22]. SPARC showed the maximum expression levels on
the 12th day of differentiation. Finally,VDR was maximally
expressed on the 21st day, concomitant with matrix
mineralization. In all cases, the data obtained from BS
patient showed that the expected expression profiles were
quite similar to that of healthy donors, unlike the observed
for OI patients. The gene expression of osteogenesis
markers evaluated in this study suggested that, at least
during osteogenic differentiation, BS-BMSCs are closer to
healthy MSCs than to OI-BMSCs.
According to Stolzing et. al (2008), previous studies
have addressed the effects of aging on MSCs, reporting
age-related changes in MSCs, including loss of prolifera-
tion and differentiation potential, increases in senescent
cell number and loss of in vivo bone formation potential
[23]. In their work, they showed a progressive decline of
specific ALP activity and chondrogenic differentiation in
“aged MSC”, although adipogenic differentiation did not
change significantly with age. However, It should also be
emphasized that MSC from donors in the age range
from 7 to 18 years were referred to as “young” MSC, for
the age range 19–40 years “adult” MSC and for cells
from over 40 years old donors were named “aged” by the
authors. We cannot exclude the effect of age on the dif-
ferentiation potential of MSCs, but we consider our con-
clusions are not found to be correlated with this specific
factor, once all the OI, BS and normal subjects could be
classified as “young” or “adult”.
Given the evidence that more than one locus contrib-
utes to the etiology of BS, accurate phenotype-genotype
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correlations will be important so as to understand the
phenotypic heterogeneity of BS. Mutations in PLOD2
and FKBP10 can be a common etiology of BS, but future
studies are needed to confirm the involvement of other
genes in the heterogeneity of the phenotype.
Recent reports have detected FKBP10 mutation in pa-
tients with BS and suggested that FKBP10 deficiency
might be the cause of Type-1 Bruck Syndrome. These
results contribute to define BS as a highly heterogenic
genetic disorder wherein several genes could be involved
in the physiopathology.
Conclusion
In summary, the present study is the first one that shows
gene expression profiles of BMSCs from patients with BS
and can be important to ascertain whether there are differ-
ences in clinical course that are determined by the nature
of the underlying defect, especially considering the fact that
there are different gene-expression data sets between BS
and OI patients, at least for the genes analyzed in this study.
These changes in gene expression may be related to pheno-
typic heterogeneity found in patients and their understand-
ing may be important in determining new diagnostic
strategies.
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